Targeting upstream alarmins (TSLP, IL-33, IL-25): a new frontier in treating type 2 chronic rhinosinusitis with nasal polyps
- 1Department of Otolaryngology, Mianyang Central Hospital/The Affiliated Mianyang Hospital of University of Electronic Science and Technology
Abstract
Chronic rhinosinusitis with nasal polyps (CRSwNP) affects 1%-4% of adults globally and imposes a substantial burden on quality of life. Despite endoscopic surgery, topical corticosteroids, and systemic glucocorticoids, postoperative recurrence exceeds 54% at five years. Even with the advent of biologics targeting downstream type 2 effectors, such as dupilumab, mepolizumab, and omalizumab, a meaningful subset of patients, particularly those with mixed or non-type 2 endotypes, remains inadequately controlled. The epithelial alarmins thymic stromal lymphopoietin (TSLP), interleukin-33 (IL-33), and interleukin-25 (IL-25) occupy the apex of the inflammatory cascade, functioning as proximal triggers that bridge innate barrier disruption to adaptive type 2 amplification. This review examines the shared and distinctive pathobiology of these three molecules in CRSwNP, compares the clinical trajectories of tezepelumab (Phase 3), anti-IL-33/ST2 agents (Phase 2/3), and emerging anti-IL-25 biologics (early-phase), and outlines a conceptual framework for future investigation. We propose that upstream alarmin inhibition offers a broader immunomodulatory scope than downstream cytokine blockade, yet its clinical translation hinges on three unresolved challenges: overcoming functional redundancy among alarmins, defining the long-term safety profile of sustained epithelial-immune suppression, and validating clinically accessible predictive biomarkers. The proposed algorithms and biomarker cut-offs remain exploratory and require prospective validation in CRSwNP-specific cohorts.
Related
- PHEnotyping type 2 inflammation in chronic rhinosinusitis with nasal polyps (CRSwNP) using RHeology of sinonasal secretions and tissue EOsinophil mapping in the middle turbinate
- Analysis of immediate upstream gene regions in orthopoxvirus genomes through the use of DNA Duplex Stability and explainable machine learning
- TL1A morphological shifts and inflammatory heterogeneity in rhinosinusitis and allergic rhinitis: a hypothesis-driven review
- Case Report: Olfactory loss as the sentinel manifestation of type 2 chronic rhinosinusitis without polyps: response to IL-4Rα inhibition with stapokibart - a case series
- Editorial: BCIs for monitoring and treating mental health conditions
BibTeX
@article{li2026targeting,
title = {{Targeting upstream alarmins (TSLP, IL-33, IL-25): a new frontier in treating type 2 chronic rhinosinusitis with nasal polyps}},
author = {Shuhua Li},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1970480},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1970480/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Targeting upstream alarmins (TSLP, IL-33, IL-25): a new frontier in treating type 2 chronic rhinosinusitis with nasal polyps
AU - Shuhua Li
PY - 2026
DA - 2026/10/09
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1970480
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1970480/full
AB - Chronic rhinosinusitis with nasal polyps (CRSwNP) affects 1%-4% of adults globally and imposes a substantial burden on quality of life. Despite endoscopic surgery, topical corticosteroids, and systemic glucocorticoids, postoperative recurrence exceeds 54% at five years. Even with the advent of biologics targeting downstream type 2 effectors, such as dupilumab, mepolizumab, and omalizumab, a meaningful subset of patients, particularly those with mixed or non-type 2 endotypes, remains inadequately controlled. The epithelial alarmins thymic stromal lymphopoietin (TSLP), interleukin-33 (IL-33), and interleukin-25 (IL-25) occupy the apex of the inflammatory cascade, functioning as proximal triggers that bridge innate barrier disruption to adaptive type 2 amplification. This review examines the shared and distinctive pathobiology of these three molecules in CRSwNP, compares the clinical trajectories of tezepelumab (Phase 3), anti-IL-33/ST2 agents (Phase 2/3), and emerging anti-IL-25 biologics (early-phase), and outlines a conceptual framework for future investigation. We propose that upstream alarmin inhibition offers a broader immunomodulatory scope than downstream cytokine blockade, yet its clinical translation hinges on three unresolved challenges: overcoming functional redundancy among alarmins, defining the long-term safety profile of sustained epithelial-immune suppression, and validating clinically accessible predictive biomarkers. The proposed algorithms and biomarker cut-offs remain exploratory and require prospective validation in CRSwNP-specific cohorts.
SN - 1664-3224
ER -